A New Strategy for Trichomonas Testing Female Adolescents in the Emergency Department

• Published in: Journal of pediatric & adolescent gynecology Vol. 29; no. 4; pp. 378 - 381
• Main Authors: Territo, Heather M., Wrotniak, Brian H., Bouton, Scott, Burstein, Gale R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2016
• Subjects: Adolescent; Adolescents; Antigens, Protozoan - analysis; Cervix Uteri - parasitology; Emergency Service, Hospital; Female; Humans; Nucleic Acid Amplification Techniques - methods; OSOM rapid Trichomonas Testing; Prospective Studies; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Sexually Transmitted Diseases - diagnosis; Sexually Transmitted Diseases - parasitology; Trichomonas vaginalis; Trichomonas vaginalis - immunology; Trichomonas vaginalis - isolation & purification; Trichomonas Vaginitis - diagnosis; Trichomonas Vaginitis - parasitology; Vagina - parasitology; Young Adult; Trichomonas vaginalis; Adolescents; OSOM rapid Trichomonas Testing
• ISSN: 1083-3188; 1873-4332
• DOI: 10.1016/j.jpag.2016.01.120

Sensitive trichomonas diagnostic testing has become available, including nucleic acid amplification tests (NAATs) and a rapid antigen test. The study purpose was to determine if adding sensitive trichomonas testing to routine female sexually transmitted infection (STI) evaluations would increase trichomonas identification and treatment. Two study time periods. Study time 1 (T1) was used for a retrospective review. Study time 2 (T2) was used for a prospective study. Emergency Department. Symptomatic female patients aged 13-20 years (N = 447). Implementation of routing trichomonas testing in the Emergency Department during T2. Trichomonas diagnosis and treatment rates were compared during T1 and T2. During T1 31 of 234 of eligible patients (13%) were trichomonas-tested. Laboratory-confirmed trichomonas was identified in 3 of 234 (1.3%). During T2, 212 of 213 of eligible patients (99.5%) were trichomonas-tested; 39 of 212 tested trichomonas-positive (18.4%); 29 of 212 tested rapid trichomonas antigen test-positive (13.6%; P < .001), and 33 of 188 tested trichomonas NAAT-positive (15.5%; P < .001). Trichomonas treatment was given to 3 of 3 laboratory-confirmed trichomonas cases during T1 (100%) compared with 37 of 39 during T2 (95%; P = .688). During T1, 14 of 17 women who received trichomonas treatment (82.4%) did not have a laboratory-confirmed trichomonas diagnosis and during T2 13 of 52 women without a laboratory-confirmed trichomonas diagnosis (25%) were treated for trichomonas (P < .001). Rapid trichomonas antigen tests and trichomonas NAATs were concordant in 178 of 188 patients (94.6%). Incorporating trichomonas rapid antigen tests and NAATs into routine female adolescent STI testing significantly increased the number of laboratory-confirmed adolescent trichomonas diagnosis and treatment and are useful Emergency Department STI screening tools.